CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders,…
SPAC & De-SPAC Trading Stats (10/14/26) SPAC trading turned sharply lower as $BKHA plunged 38% and $RFAI dropped 21% while $ALIS rebounded 8%, and De-SPAC volatility intensified with $GLND surging 76% on heavy volume as $CDT collapsed 47%. SPACs (DA partner): – $ALIS…
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $0 | — | $-39.22M |
| 2024 | $0 | — | $-17.8M |
| 2023 | $0 | — | $-535K |
Stock data for CDT: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics